Literature DB >> 11313038

Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia.

D D Miller1, N C Andreasen, D S O'Leary, G L Watkins, L L Boles Ponto, R D Hichwa.   

Abstract

BACKGROUND: Atypical antipsychotics, such as risperidone, have been shown to be more effective for the treatment of the symptoms of schizophrenia and have a greater beneficial effect on neurocognition compared to the conventional antipsychotics. The present study used [(15)O]H(2)O positron emission tomography imaging of regional cerebral blood flow to examine and compare the effects of haloperidol and risperidone on brain function.
METHODS: Thirty-two subjects with schizophrenia participated in the study. Each subject was scanned in a medication-free state, and after being on a stable clinically assigned dose of either risperidone or haloperidol for 3 weeks. The off-medication scan was subtracted from the on-medication scan, using a within-subjects design. A randomization analysis was used to determine differences between the effects of haloperidol and risperidone on regional cerebral blood flow.
RESULTS: Haloperidol was associated with a significantly greater increase in regional cerebral blood flow in the left putamen and posterior cingulate, and a significantly greater decrease in regional cerebral blood flow in frontal regions compared to risperidone. Risperidone was associated with a significantly greater decrease in regional cerebral blood flow in the cerebellum bilaterally compared to haloperidol.
CONCLUSIONS: The results show that risperidone and haloperidol have significantly different effects on brain function, which may be related to their differences in efficacy and side effects. Further work is required to more precisely determine the mechanisms by which different antipsychotic medications exert their therapeutic effects on the clinical symptoms and cognition in schizophrenia. These findings emphasize the importance of controlling for both medication status and the individual antipsychotic in neuroimaging studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313038     DOI: 10.1016/s0006-3223(00)01001-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  30 in total

1.  Functional neuroimaging in mental disorders.

Authors:  Philip K McGuire; Kazunori Matsumoto
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

2.  Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

Authors:  B E H Sumner; L A Cruise; D A Slattery; D R Hill; M Shahid; B Henry
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

3.  Consensus paper: the cerebellum's role in movement and cognition.

Authors:  Leonard F Koziol; Deborah Budding; Nancy Andreasen; Stefano D'Arrigo; Sara Bulgheroni; Hiroshi Imamizu; Masao Ito; Mario Manto; Cherie Marvel; Krystal Parker; Giovanni Pezzulo; Narender Ramnani; Daria Riva; Jeremy Schmahmann; Larry Vandervert; Tadashi Yamazaki
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

4.  Effects of amisulpride on human resting cerebral perfusion.

Authors:  Roberto Viviani; Heiko Graf; Maike Wiegers; Birgit Abler
Journal:  Psychopharmacology (Berl)       Date:  2013-04-13       Impact factor: 4.530

Review 5.  Use of magnetic resonance imaging in pharmacogenomics.

Authors:  Roberto Viviani; Marie-Louise Lehmann; Julia C Stingl
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

6.  Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment.

Authors:  Mohamed Ahmed; Dara M Cannon; Cathy Scanlon; Laurena Holleran; Heike Schmidt; John McFarland; Camilla Langan; Peter McCarthy; Gareth J Barker; Brian Hallahan; Colm McDonald
Journal:  Neuropsychopharmacology       Date:  2015-04-01       Impact factor: 7.853

7.  Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.

Authors:  Euitae Kim; Oliver D Howes; Mattia Veronese; Katherine Beck; Seongho Seo; Jin Woo Park; Jae Sung Lee; Yun-Sang Lee; Jun Soo Kwon
Journal:  Neuropsychopharmacology       Date:  2016-11-18       Impact factor: 7.853

8.  Does baseline cerebral blood flow affect task-related blood oxygenation level dependent response in schizophrenia?

Authors:  Jiacheng Liu; Maolin Qiu; R Todd Constable; Bruce E Wexler
Journal:  Schizophr Res       Date:  2012-07-11       Impact factor: 4.939

9.  Influence of obstetric complication severity on brain morphology in schizophrenia: an MR study.

Authors:  G Bersani; A Quartini; G Manuali; A Iannitelli; D Pucci; F Conforti; C Di Biasi; G Gualdi
Journal:  Neuroradiology       Date:  2009-02-13       Impact factor: 2.804

10.  Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement.

Authors:  Vicente Molina; Juan D Gispert; Santiago Reig; Javier Sanz; Javier Pascau; Andrés Santos; Manuel Desco; Tomás Palomo
Journal:  Psychopharmacology (Berl)       Date:  2004-09-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.